Navigation Links
ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Date:11/1/2007

ibit angiogenesis in diseased conditions, without, importantly, affecting normal blood vessels in healthy tissues.

These findings pave the way for the development of a new class of improved cancer therapeutics which could have a complementary mechanism of action and potentially enhanced safety profile in comparison to existing angiogenesis inhibitors.

Angiogenesis inhibitors are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer tumour cells of oxygen and nutriments. This approach in turn is thought to stop the tumour from growing and spreading to other parts of the body. Currently available angiogenesis inhibitors specifically target vascular endothelial growth factor (VEGF), which plays an important role in promoting the formation of blood vessels. However, since VEGF inhibitors also act on healthy tissue, their therapeutic potential is hampered by side effects. Although PlGF is a homologue of VEGF, it does not affect normal, physiological angiogenesis and is only involved in the angiogenesis process which takes place in the diseased tissue.

Based on its anti-angiogenic properties, ThromboGenics and BioInvent also intend to develop TB-403 for eye diseases, to block uncontrolled blood vessel growth in conditions such as age-related macular degeneration (AMD) and diabetic retinopathy.

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commented: "Today's publication in the prestigious journal Cell clearly highlights our ground-breaking research in the field of angiogenesis. The data in the Cell paper shows the potential of our novel anti-PlGF antibody, TB-403, based on its unique ability to block the development of new blood vessels, but only via mechanisms that exist in the diseased state. This mode of action, which is different from and complementary to current anti-VEGF inhibitors, makes it attractive as both a stand-alone and combination therapy. I am very excited that we w
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that Innovative ... e-Journal and producer of Food Labs Conference , ... the co-location of Food Labs Conference to be held in ... fee to attend the two-day Food Lab Conference, March 4-5. ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... has been created that contains antibodies against coccidiosis, a ... writing in the open access journal BMC Biotechnology ... demonstrate their effectiveness in preventing this economically important illness. ... from Novoplant GmbH, Germany, to develop the seeds. He ...
... In a development that holds much promise for the ... use of solar energy to produce clean and renewable ... Energy,s Lawrence Berkeley National Laboratory (Berkeley Lab) have reported ... crystals of the semiconductor cadmium-selenide was increased 100,000 times. ...
... OAKS, Calif., Sept. 11 Amgen (Nasdaq: AMGN ) ... Monday, Sept. 14, 2009, at the Grand Hyatt hotel in New ... CEO Kevin Sharer will present at the conference. Live audio of ... accessed from Amgen,s Web site, www.amgen.com, under Investors. , ...
Cached Biology Technology:Gold solution for enhancing nanocrystal electrical conductance 2Gold solution for enhancing nanocrystal electrical conductance 3Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:4/23/2014)... hungry diner ripping open a dinner roll, a fuel ... open a hydrogen molecule. Now researchers have captured a ... halves of its hydrogen feast. The view confirms previous ... catalyst work better for alternative energy uses. , This ... where the hydrogen halves end up in the structure ...
(Date:4/23/2014)... This news release is available in French ... , Montreal, 23 April 2014Today, the CEC released ... A Binational Collaborative Approach to Conservation, which identifies 29 ... States-Mexico border that includes 11 different protected areas in ... features unique, highly diverse arid and semi-arid habitats inhabited ...
(Date:4/23/2014)... A team of researchers in Korea ... the brains of nonhuman primates and assessed cell ... found that the hNSCs had differentiated into neurons ... , The study will be published in a ... is currently freely available on-line as an unedited ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... at the University of Southampton today, Monday 23 August, ... in Europe, Photon10, the latest developments in ,green photonics, ... technologies undertaken by the United States, Optoelectronics Development Association ... will help reduce CO 2 -creating energy consumption will ...
... Jodie Holt , a professor of plant physiology at ... James Cameron,s film Avatar , will receive ... work as a distinguished scientist and educator" at a ceremony ... Diego Botanic Garden, 230 Quail Gardens Drive, Encinitas, Calif. ...
... NY, August 20, 2010The U.S. needs a comprehensive and ... it remains competitive in the global science and technology ... latest issue of OMICS: A Journal of Integrative ... Liebert, Inc. ( www.liebertpub.com ). The commentary is available ...
Cached Biology News:$240 billion of green photonics by 2021 2A plan to promote sustainable US scientific discovery and innovation in the 21st century is proposed in OMICS 2
... SeMet White to off-white solid. Increases the ... HPLC. Soluble in H 2 O. ... use. RTECS EK7713840, CAS 3211-76-5, M.W. 196.1. ... 8515.Jornot, L., and Junod, A.F. 1995. ...
... pen has been designed to provide a thin film-like ... on a slide. This barrier creates the proper ... target area on the slide. PAP Pen contains ... acetone. It can be removed, if desired, by ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
...
Biology Products: